Supplements

Potassium

Updated · 56 sources

Potassium is an essential mineral and the main positive ion inside cells. The steep difference between potassium inside and outside cells is what lets nerves fire, muscles contract and the heart keep its rhythm. Adults in the US generally eat less than the Adequate Intake, and higher intake modestly lowers blood pressure, mostly in people with hypertension.

The most important safety fact is that the kidneys decide whether potassium is harmless or dangerous. With normal kidney function, food potassium poses no known risk, and no upper limit has been set. With kidney disease, or with drugs such as spironolactone, lisinopril or losartan, the same intake can cause hyperkalemia (high blood potassium), which may produce no symptoms before a fatal arrhythmia. Over-the-counter pills are usually limited to 99 mg, while prescription tablets hold up to about eight times that and salt substitutes can hold far more.

This page summarizes what the National Academies, the NIH Office of Dietary Supplements, FDA labels, clinical trials and meta-analyses report. It is for education only and is not medical advice. For hydration, sweat losses and sodium, see Electrolytes.

Property Detail
Type Essential mineral; food component, dietary supplement and prescription drug
Adequate Intake (adults) 3,400 mg/day (men); 2,600 mg/day (women)
Upper limit None set; the National Academies found too little evidence of toxicity in healthy people
Normal serum level About 3.6–5.0 mmol/L
Over-the-counter supplements Most contain up to 99 mg per serving, about 2% of the 4,700 mg Daily Value
Prescription potassium chloride Klor-Con M: 10, 15 and 20 mEq tablets (≈391, 587 and 782 mg potassium)
Labeled doses (potassium chloride) Typically 20 mEq/day to prevent low potassium; 40–100 mEq/day or more to treat depletion
Salt substitutes About 440–2,800 mg potassium per teaspoon
Half-life No single value applies to a nutrient held mostly inside cells; not listed here
WADA status Not named on the 2026 Prohibited List; diuretics are prohibited (S5)

What it is

The adult body holds about 45 mmol of potassium per kg of body weight, or about 140 g in a 175 lb adult. Most of it sits inside cells. The concentration inside cells is about 30 times higher than outside, a gradient maintained by the sodium-potassium pump (Na+/K+ ATPase) (NIH ODS). The Klor-Con label gives about 150–160 mEq/L inside cells and 3.5–5 mEq/L in plasma (Klor-Con M label).

Doses are written in two units. One mmol equals 1 mEq, which equals 39.1 mg of potassium (NIH ODS). Supplement Facts panels list elemental potassium, not the weight of the whole salt. A Klor-Con M10 tablet holds 750 mg of potassium chloride but delivers 10 mEq, or about 391 mg, of potassium.

Dietary reference intakes

In 2019, a National Academies committee set only Adequate Intakes (AIs) for potassium. These were based on the highest median intakes seen in healthy people, not on a measured requirement, because the data could not support an average requirement or RDA (NASEM 2019).

Group AI, male (mg/day) AI, female (mg/day)
1–3 years 2,000 2,000
4–8 years 2,300 2,300
9–13 years 2,500 2,300
14–18 years 3,000 2,300
19 years and older 3,400 2,600
Pregnancy, 19–50 years Not applicable 2,900
Lactation, 19–50 years Not applicable 2,800

Source: NIH ODS. These AIs do not apply to people whose potassium excretion is impaired by kidney disease or medication.

Other bodies use higher numbers, and they differ in purpose:

  • Daily Value. The FDA label value is 4,700 mg/day (NIH ODS).
  • WHO. WHO suggests at least 90 mmol/day (3,510 mg/day) for adults, as a conditional recommendation (WHO 2025).
  • AHA/ACC. The 2025 hypertension guideline lists an aim of 3,500–5,000 mg/day, ideally from a potassium-rich diet, as a blood pressure measure (Jones et al., Circulation 2025).

In NHANES 2013–2014, average intake from food was 3,016 mg/day in men and 2,320 mg/day in women aged 20 and over (NIH ODS). The committee cautioned that because it is unknown how the AI relates to actual requirements, an intake below the AI cannot be read as inadequate (NASEM 2019).

Why no upper limit was set

The committee reviewed case reports, supplement trials and blood data, and found the following (NASEM 2019):

  • Very large supplement doses can cause cardiac abnormalities and death in case reports, but the doses are imprecise and confounded by illness and medication.
  • Supplements may slightly raise blood potassium, yet there is no evidence they cause hyperkalemia (defined by the committee as above 5.5 mmol/L) in adults with normal kidney function.
  • Supplement trials showed no consistent pattern of adverse events.

It therefore concluded the evidence was insufficient to set a Tolerable Upper Intake Level. The committee was explicit about what this means: “the absence of a potassium UL does not mean there is no risk from excessive intake.” It called for caution with supplemental potassium in people with or at high risk of compromised kidney function.

The ODS adds that up to 15,600 mg/day of supplemental potassium for 5 days raised plasma potassium in healthy people without leaving the normal range. Very high amounts could still exceed the kidneys’ capacity and cause acute hyperkalemia, even in healthy people (NIH ODS).

Food sources

Selected values from the ODS table, based on USDA data (NIH ODS):

Food Potassium per serving
Dried apricots, ½ cup 755 mg
Lentils, cooked, 1 cup 731 mg
Potato, baked, flesh only, 1 medium 610 mg
Orange juice, 1 cup 496 mg
Banana, 1 medium 422 mg
Milk, 1%, 1 cup 366 mg
Chicken breast, grilled, 3 ounces 332 mg
Salmon, farmed, cooked, 3 ounces 326 mg

Milk, coffee, tea, other nonalcoholic drinks and potatoes are the top sources for US adults. Potassium in fruits and vegetables comes as phosphate, sulfate, citrate and other salts, not as the chloride used in salt substitutes and many supplements.

Supplement forms and the 99 mg limit

Form Where it appears Notes
Potassium chloride Supplements, salt substitutes, prescription tablets, powders and liquids The usual drug for low potassium with metabolic alkalosis, and the main form in blood pressure trials
Potassium citrate Supplements; prescription Urocit-K (10 and 15 mEq) Labeled for renal tubular acidosis and certain kidney stones
Potassium gluconate Supplements Absorption over 94%, matching potatoes, in a crossover trial of 35 adults
Potassium bicarbonate, phosphate, aspartate Supplements Few absorption data
Potassium iodide Some supplements, in microgram amounts A source of iodine, not of potassium

Sources: NIH ODS; Klor-Con M label; Urocit-K label; Macdonald-Clarke et al., Am J Clin Nutr 2016.

The 99 mg figure is mostly an industry practice, not a legal ceiling on supplements. It traces back to rules for drugs:

  • Withdrawn drug forms. FDA lists solid oral potassium chloride drugs supplying 100 mg or more of potassium per unit as withdrawn for safety or effectiveness reasons. Controlled-release forms and products made to be dissolved before use are excepted (21 CFR 216.24).
  • Required warning. Coated tablets of potassium salts supplying 100 mg or more must carry a warning about small-bowel lesions that have caused obstruction, hemorrhage and perforation, with deaths reported (21 CFR 201.306).
  • Supplements. FDA has not ruled on whether supplements above 99 mg need that warning, and it may limit a nutrient in a supplement only for safety reasons. Many makers stay at 99 mg because of these two drug rules (NIH ODS).

The result is a wide gap between products:

Product Potassium per unit
Typical multivitamin that contains potassium About 80 mg
Typical potassium-only supplement Up to 99 mg (≈2.5 mEq)
Prescription Klor-Con M20 tablet 20 mEq (≈782 mg)
Salt substitute, 1 teaspoon About 440–2,800 mg

About 12% of Americans use a potassium-containing supplement, and it adds a mean of only 87 mg/day among users (NIH ODS). These pills do little to close an intake gap, which is why food and salt substitutes carry most of the evidence.

How it works in the body

About 85%–90% of dietary potassium is absorbed, by passive diffusion and mainly in the small intestine. The kidneys excrete most of it and adjust excretion rapidly to intake. Some leaves in stool and a very small amount in sweat (NIH ODS). Sweat and hydration are covered on Electrolytes.

Blood potassium is a poor guide to total stores, because so little of the body’s potassium is in blood. It also moves in and out of cells without any change in total body content. The label notes that acute alkalosis can produce hypokalemia without a real deficit, and that acute acidosis can push a depleted person’s serum level into the normal range. Depletion sufficient to cause hypokalemia usually requires losing 200 mEq or more (≈7,800 mg) from body stores (Klor-Con M label).

Exercise shows how fast these shifts are. Working muscle releases potassium, and the sodium-potassium pump clears it. In 11 endurance-trained or sprint-trained people, 1 minute of exhausting running raised femoral venous plasma potassium by about 4.4–4.7 mmol/L. Three minutes after stopping, it sat about 0.5 mmol/L below the starting level (Medbø & Sejersted, Acta Physiol Scand 1994).

Approved medical use

Prescription potassium chloride is labeled for treating hypokalemia with or without metabolic alkalosis, digitalis intoxication and hypokalemic familial periodic paralysis. It is also labeled to prevent hypokalemia in people at particular risk, such as those on digitalis or with significant arrhythmias (Klor-Con M label). Key points from that label:

  • Dose. Typically 20 mEq/day for prevention and 40–100 mEq/day or more for treating depletion. Doses above 20 mEq/day are divided so that no single dose exceeds 20 mEq.
  • Diuretic users. Potassium salts are “often unnecessary” in people taking low-dose diuretics for uncomplicated hypertension who eat a normal diet. Lowering the diuretic dose is suggested as a first consideration when a diuretic causes hypokalemia.
  • Liquids first. The label reserves controlled-release solid forms for people who cannot tolerate, or will not take, liquid or effervescent preparations.

Urocit-K (potassium citrate) is labeled for renal tubular acidosis, low-citrate calcium oxalate kidney stones and uric acid stones, starting at 30–60 mEq/day depending on severity (Urocit-K label).

What the research shows

Blood pressure

Potassium supplements lower blood pressure, and the effect is concentrated in people with hypertension. The trials are mostly small and short, and results vary widely between them.

Meta-analysis Trials and participants Population Systolic / diastolic change (mm Hg)
Whelton et al., JAMA 1997 33 RCTs, 2,609 Mixed −3.11 / −1.97, excluding one outlier trial
Dickinson et al., Cochrane 2006 6 RCTs, 483 (5 trials, 425 pooled) Raised blood pressure; at least 8 weeks −11.2 (95% CI −25.2 to 2.7) / −5.0 (95% CI −12.5 to 2.4); not significant
Aburto et al., BMJ 2013 22 RCTs, 1,606 Adults −3.49 / −1.96; seen with hypertension, not without
Binia et al., J Hypertens 2015 15 RCTs, 917 Not on blood pressure drugs −4.7 / −3.5 overall; −6.8 / −4.6 with hypertension
Filippini et al., Int J Cardiol 2017 25 RCTs, 1,163 Hypertension −4.48 / −2.96
Ravichagua Ashiyama et al., JAHA 2026 19 RCTs, 803 Untreated hypertension; median 4 weeks Clinic −5.3 / −4.5; 24-hour ambulatory −2.8 / −3.2

Trial participants in the 2017 analysis took mostly potassium chloride at 30–120 mmol/day (1,173–4,692 mg), for 4–15 weeks (NIH ODS). Several findings qualify the headline numbers:

  • The 2006 Cochrane review was not significant. It stayed inconclusive because of few participants, short follow-up and unexplained differences between trials. It remains the main dissent, and it predates most of the later pooled analyses.
  • Little effect without hypertension. A dose-response analysis of 10 RCTs estimated that 50 mmol/day more urinary potassium goes with −5.3 / −3.62 mm Hg with hypertension but only −0.5 / −0.12 mm Hg without it. The authors urged caution because the trials were few (Granal et al., Clin Kidney J 2025).
  • More is not clearly better. In 32 trials, the blood pressure benefit weakened beyond a 30 mmol/day difference between trial arms. Pressure rose above a difference of about 80 mmol/day, mainly in people already on blood pressure drugs. The authors said the high-intake estimates rest on few trials (Filippini et al., JAHA 2020).
  • Side effects. In the 2026 analysis, adverse events were more frequent with potassium (12.8% vs 3.2%), and the authors called for cautious interpretation because of heterogeneity and short follow-up.

The National Academies rated the blood pressure evidence as moderate strength. It still declined to set a chronic disease intake target, citing that heterogeneity, the lack of a clear dose-response and insufficient evidence on heart disease outcomes (NASEM 2019). The committee also noted that the independent effect of potassium intake on death, heart disease and stroke has not been tested in randomized trials. Observational links to stroke do exist: in 11 cohorts with 127,038 participants, higher intake was associated with 24% lower stroke risk (Aburto et al., BMJ 2013). These associations may be confounded by the rest of the diet.

Salt substitutes: stroke and mortality

Potassium-enriched salt replaces part of the sodium chloride with potassium chloride, so it lowers sodium and raises potassium at once. That means these trials cannot isolate potassium’s own effect. An AHRQ review found that at least some of the blood pressure benefit may come from the sodium reduction (NIH ODS).

The Salt Substitute and Stroke Study (SSaSS) is the only large trial with hard outcomes. This open-label trial randomized 600 rural Chinese villages and enrolled 20,995 people who had a prior stroke, or who were 60 or older with high blood pressure. The substitute was 75% sodium chloride and 25% potassium chloride, and mean follow-up was 4.74 years (Neal et al., N Engl J Med 2021):

Outcome Salt substitute (per 1,000 person-years) Regular salt (per 1,000 person-years) Rate ratio (95% CI)
Stroke (primary) 29.14 33.65 0.86 (0.77–0.96)
Major cardiovascular events 49.09 56.29 0.87 (0.80–0.94)
Death from any cause 39.28 44.61 0.88 (0.82–0.95)
Serious adverse events attributed to hyperkalemia 3.35 3.30 1.04 (0.80–1.37)

A prespecified analysis of the 15,249 participants with prior stroke found fewer recurrent strokes (RR 0.86; 95% CI 0.77–0.95) and deaths (RR 0.88; 95% CI 0.82–0.96), with no difference in clinical hyperkalemia (RR 1.01; 95% CI 0.74–1.38) (Ding et al., JAMA Cardiol 2025).

Other trials and pooled analyses add to this picture:

  • DECIDE-Salt. 48 Chinese elderly care facilities (1,612 participants) were randomized over 2 years to a substitute with 62.5% sodium chloride and 25% potassium chloride, or usual salt. Systolic pressure fell by 7.1 mm Hg (95% CI 3.8–10.5) and cardiovascular events were lower (HR 0.60; 95% CI 0.38–0.96). Total mortality did not differ significantly (HR 0.84; 95% CI 0.63–1.13) (Yuan et al., Nat Med 2023).
  • Normal blood pressure. In a post hoc DECIDE-Salt analysis of 611 older adults, new hypertension was less common with the substitute (11.7 vs 24.3 per 100 person-years; adjusted HR 0.60; 95% CI 0.39–0.92), without more low blood pressure episodes (Zhang et al., J Am Coll Cardiol 2024).
  • Cochrane 2022. In 26 RCTs, substitutes probably lowered blood pressure (−4.76 / −2.43 mm Hg), and non-fatal cardiovascular events and cardiovascular death slightly, with moderate-certainty evidence (Brand et al., Cochrane 2022).
  • Heart 2022. In 21 trials with 31,949 participants, total mortality fell (RR 0.89; 95% CI 0.85–0.94), as did cardiovascular events (RR 0.89; 95% CI 0.85–0.94) (Yin et al., Heart 2022).
  • Network meta-analysis 2026. In 34 RCTs with 37,063 participants, substitutes with 25%–40% potassium chloride probably reduced deaths and cardiovascular events. However, the benefit was driven largely by SSaSS: excluding it removed statistical significance for all-cause mortality, and no trial outside China contributed mortality data (Lai et al., BMC Med 2026).

Salt substitutes: hyperkalemia

The reassuring safety results have clear limits:

  • Selected participants. All 26 trials in the Cochrane review excluded people in whom extra potassium is known to be potentially harmful. The review found little to no difference in hyperkalemia (4 more per 100,000; 95% CI 47 fewer to 121 more) but a slight rise in blood potassium (0.12 mmol/L), and it could not draw conclusions about safety for the general population (Brand et al., Cochrane 2022).
  • No blood testing in SSaSS. Its pragmatic design produced no information on biochemical hyperkalemia. It counted only serious adverse events attributed to hyperkalemia (Xu et al., Hypertension 2024).
  • Lab hyperkalemia did appear when measured. DECIDE-Salt, which did not screen people out by hyperkalemia risk, found higher serum potassium and more frequent biochemical hyperkalemia, without adverse clinical outcomes (Yuan et al., Nat Med 2023). Sustained elevations were uncommon (Xu et al., Hypertension 2024).
  • Modeling in kidney disease. A BMJ model for China estimated 11,000 additional hyperkalemia-related deaths a year among people with chronic kidney disease, outweighed by averted cardiovascular deaths in that same group. These are modeled numbers, not trial results (Marklund et al., BMJ 2020).

Guidelines reflect this balance. The 2025 AHA/ACC guideline gives potassium-based substitutes a class 2a recommendation, particularly where salt is mostly added at home, “except in the presence of CKD or use of drugs that reduce potassium excretion where additional monitoring is probably indicated.” It also notes that most US sodium comes from processed and restaurant food, and that substitutes in the studied ratios have low US availability (Jones et al., Circulation 2025). WHO’s 2025 guideline suggests replacing table salt with potassium-containing substitutes (conditional recommendation) for adults only, excluding pregnant women, children and people with kidney impairment or other conditions that might compromise potassium excretion (WHO 2025).

Kidney stones and bone

  • Kidney stones. Potassium citrate reduced new stones and stone size in a Cochrane review of 7 studies, but the proposed mechanism involves citrate rather than potassium (NIH ODS). The National Academies judged the evidence on potassium intake itself insufficient (NASEM 2019).
  • Bone. Trials of potassium citrate and bicarbonate are mixed. Results may depend on the accompanying anion, so they do not necessarily reflect potassium’s own effect (NASEM 2019).

Muscle cramps

The idea that low potassium causes ordinary cramps, and that a banana fixes them, has little support:

  • Trials of treatment. A 2026 systematic review of electrolyte supplementation for cramps and muscle pain (13 trials, mostly magnesium) concluded that potassium remains unsupported (Patil et al., Int Dent J 2026). The American Academy of Neurology’s review of cramp treatments did not list potassium among the options with supporting evidence (Katzberg et al., Neurology 2010). We found no placebo-controlled trial showing that potassium prevents exercise cramps.
  • Blood levels in athletes. A 2026 meta-analysis of 9 longitudinal studies with 11,274 participants found that people who cramped had higher, not lower, post-race serum potassium. A prior history of cramps carried about 4.4-fold higher odds, and was the only factor backed by strong evidence (Costa et al., Muscle Nerve 2026).
  • Bananas. In 9 men after 60 minutes of cycling in the heat, two servings of banana (300 g) raised plasma potassium to only 4.6 mmol/L, vs 4.4 mmol/L with none, at 60 minutes. The author concluded the change was marginal and too slow to treat a cramp (Miller, J Athl Train 2012).

Drugs are a more plausible link. In a study of adults 50 and older in British Columbia, starting a cramp treatment (quinine) was more likely in the year after starting certain drugs. Sequence ratios were 2.42 for long-acting beta-agonists, 2.12 for potassium-sparing diuretics, 1.48 for thiazide-like diuretics and 1.20 (not significant) for loop diuretics (Garrison et al., Arch Intern Med 2012). The pattern does not track potassium in one direction, since potassium-sparing diuretics had one of the highest ratios.

Cramps can also signal a true potassium emergency in either direction. One bodybuilder presented with cramps at a potassium of 1.8 mmol/L, and another with weakness and cramps from life-threatening hyperkalemia (both described below). Cramps alone cannot tell the two apart, and only a blood test can. For the wider cramp literature, see Electrolytes and Magnesium.

Side effects and risks

Hypokalemia

Hypokalemia means serum potassium below about 3.6 mmol/L. It affects up to 21% of hospitalized patients, usually because of diuretics and other drugs, but it is rare in healthy people with normal kidneys. Low dietary intake alone rarely causes it (NIH ODS).

  • Mild. Constipation, fatigue, muscle weakness and malaise.
  • Moderate to severe (below about 2.5 mmol/L). Large volumes of dilute urine, glucose intolerance, muscle paralysis, poor breathing and cardiac arrhythmias.

Causes include diarrhea, vomiting, laxative abuse, refeeding after starvation, heavy sweating, dialysis and clay eating. More than 50% of people with clinically significant hypokalemia might also have magnesium deficiency, which increases urinary potassium loss, and both should be treated together (NIH ODS). See Magnesium.

Drugs that lower potassium

Drug How it lowers potassium What the label or study says
Furosemide Urinary loss Hypokalemia may develop, especially with brisk diuresis, poor oral intake, cirrhosis, or with corticosteroids, ACTH, large amounts of licorice or prolonged laxative use (Lasix label)
Hydrochlorothiazide Urinary loss Risk rises with brisk diuresis, severe cirrhosis or prolonged therapy; doses above 50 mg are “often associated with marked reductions in serum potassium” (HCTZ label)
Albuterol Shift into cells May cause significant hypokalemia in some patients, usually transient and not requiring supplements; can acutely worsen the effect of loop and thiazide diuretics, especially above the recommended dose (Ventolin HFA label)
Clenbuterol Shift into cells In a single case report, a 28-year-old woman reached 2.4 mmol/L after ingestion (Hoffman et al., J Toxicol Clin Toxicol 2001)
Insulin Shift into cells All insulins shift potassium into cells; untreated hypokalemia “may cause respiratory paralysis, ventricular arrhythmia, and death” (Humulin R label)

Shifts into cells differ from true depletion, because the total amount of potassium in the body has not necessarily changed.

Hyperkalemia

Definitions vary: the ODS uses serum potassium above 5.0 mmol/L, and the National Academies report uses above 5.5 mmol/L. Beyond kidney disease and drugs, it can occur with type 1 diabetes, heart failure, adrenal insufficiency and liver disease (NIH ODS).

The main danger is that it may give no warning. The label says hyperkalemia is usually asymptomatic and may appear only as a raised serum level (6.5–8.0 mEq/L) with characteristic ECG changes. Late signs are muscle paralysis and cardiovascular collapse from cardiac arrest (9–12 mEq/L). Oral potassium rarely causes serious hyperkalemia in people with normal excretion, but potentially fatal hyperkalemia can result when excretion is impaired (Klor-Con M label). That warning says hyperkalemia with cardiac arrest occurs most commonly with intravenous potassium, but it may also occur with oral doses.

Interactions that raise potassium

Drug What is reported
Spironolactone Risk rises with impaired kidney function, potassium supplements, potassium salt substitutes, ACE inhibitors and ARBs; label advises checking potassium within 1 week of starting or changing dose (Aldactone label). Potassium salts should not be combined with potassium-sparing diuretics to treat hypokalemia (Klor-Con M label)
ACE inhibitors, such as lisinopril Serum potassium above 5.7 mEq/L occurred in 2.2% of treated hypertension patients and 4.8% of heart failure patients in trials; patients are told not to use potassium salt substitutes without consulting their physician (Zestril label)
ARBs, such as losartan Monitor potassium periodically; other drugs that raise potassium may lead to hyperkalemia; adding an ACE inhibitor raised hyperkalemia in VA NEPHRON-D without added benefit (Cozaar label)
Trimethoprim (often with sulfamethoxazole) High doses raise potassium in a substantial number of patients; even recommended doses can cause hyperkalemia with kidney insufficiency or other potassium-raising drugs (Bactrim label)
NSAIDs, such as ibuprofen May retain potassium by reducing kidney prostaglandin E and impairing the renin-angiotensin system; monitor with potassium chloride (Klor-Con M label)

Population studies show the size of these risks, all in older adults:

Study Who and what Result
Juurlink et al., N Engl J Med 2004 Ontario, age 66 and older, on ACE inhibitors after heart failure admission, as spironolactone use rose after the RALES trial Hospitalization for hyperkalemia rose from 2.4 to 11.0 per 1,000 patients (1994–2001); associated deaths rose from 0.3 to 2.0 per 1,000
Antoniou et al., Arch Intern Med 2010 On ACE inhibitor or ARB; trimethoprim-sulfamethoxazole vs amoxicillin Hyperkalemia hospitalization, adjusted OR 6.7 (95% CI 4.5–10.0)
Fralick et al., BMJ 2014 On ACE inhibitor or ARB; same antibiotic comparison Sudden death within 7 days, adjusted OR 1.38 (95% CI 1.09–1.76)
Antoniou et al., CMAJ 2015 On spironolactone; same antibiotic comparison Sudden death within 14 days, adjusted OR 2.46 (95% CI 1.55–3.90)
Crellin et al., BMJ 2018 UK, age 65 and older, urinary infection; trimethoprim vs amoxicillin Hyperkalemia, adjusted OR 2.27 (95% CI 1.49–3.45); death not higher (adjusted OR 0.90; 95% CI 0.76–1.07)
Lim et al., Drugs Aging 2021 Singapore, age 60 and older; short-course systemic NSAIDs vs no NSAID Acute kidney injury and/or hyperkalemia combined, adjusted OR 1.59 (95% CI 1.41–1.80)

These are observational and cannot prove cause. The Crellin study did not confirm the excess deaths seen in the Canadian work, though it estimated 18 additional hyperkalemia cases per 1,000 urinary infections treated with trimethoprim instead of amoxicillin in people on both a renin-angiotensin blocker and spironolactone. The NSAID estimate combines two outcomes, so it does not measure hyperkalemia alone. The furosemide label also carries case reports of raised potassium when combined with NSAIDs (Lasix label).

Kidney disease

The AIs do not apply here, and intake below the AI can still cause hyperkalemia in people with chronic kidney disease (CKD) (NIH ODS). Newer work has complicated the old advice to simply restrict potassium:

  • Potassium chloride in CKD. In 191 patients with moderately to severely reduced kidney function (mean eGFR 31; 83% on renin-angiotensin inhibitors), 40 mmol/day for 2 weeks raised plasma potassium from 4.3 to 4.7 mmol/L. Blood pressure did not change. Hyperkalemia developed in 21 people (11%), mainly older patients and those with higher starting levels. This was an uncontrolled run-in phase, and the authors called for longer studies (Gritter et al., J Am Soc Nephrol 2022).
  • Dietary restriction. A meta-analysis of 7 studies with 3,489 participants found very low-quality evidence that restriction lowers serum potassium by 0.22 mEq/L. Effects on death and disease progression were uncertain (Morris et al., J Ren Nutr 2022).
  • Food vs added salts. A KDIGO conference described data suggesting a shift from dietary restriction toward eating patterns tied to better outcomes, and noted sparse evidence that diet changes correct abnormal serum potassium (Clase et al., Kidney Int 2020). A 2026 review argues that the source matters: soluble potassium salts, including those in food additives, raise serum potassium more readily than whole foods. It stresses that direct evidence on additives is still needed (Bernier-Jean et al., Semin Nephrol 2026).

Gastrointestinal injury

Solid potassium chloride can damage the gut wall when it dissolves in one spot. The Klor-Con M label reports (Klor-Con M label):

  • Small-bowel lesions. Based on spontaneous reports, 40–50 per 100,000 patient-years with enteric-coated forms vs under 1 per 100,000 with wax matrix forms. No such comparison is available for microencapsulated products.
  • Contraindications. All solid oral forms are contraindicated with any structural, pathological (such as diabetic gastroparesis) or drug-related (anticholinergics) cause of delayed passage through the gut.
  • Esophageal ulcers. Reported in some cardiac patients with esophageal compression from an enlarged left atrium.
  • Common effects. Nausea, vomiting, gas, abdominal pain and diarrhea. Serious reports include obstruction, bleeding, ulceration and perforation.

The Urocit-K label adds peptic ulcer disease as a contraindication, and lists “strenuous physical exercise in unconditioned individuals” among conditions predisposing to hyperkalemia (Urocit-K label).

Diuretics and potassium in bodybuilding

Case reports show harm in both directions when diuretics are used before contests:

  • Too low. A 22-year-old bodybuilder misusing triamterene/hydrochlorothiazide with fluid restriction developed cramps and weakness of all four limbs, with potassium of 1.8 mmol/L and a QTc of 625 ms. He recovered within 2 days of treatment (Pfisterer et al., Clin J Sport Med 2020).
  • Too high, with supplements. A 27-year-old professional using diuretics, potassium supplements and dietary restriction had profound weakness, cramps, ECG changes and life-threatening hyperkalemia. The report notes a similar professional who died (Sturmi & Rutecki, Phys Sportsmed 1995).
  • Too high, with a mixed regimen. A 31-year-old on anabolic steroids, amphetamines, furosemide with amiloride, and potassium supplements collapsed with a heart attack, a potassium of 6.7 mmol/L and ventricular tachycardia (Appleby et al., Int J Cardiol 1994).

These are isolated reports and cannot give rates. They do illustrate the label warning about combining potassium salts with potassium-sparing diuretics.

In the US, low-dose potassium is sold as a dietary supplement and in foods, and higher-dose oral potassium products are prescription drugs. FDA allows a health claim that diets with good sources of potassium and low in sodium “may reduce the risk of high blood pressure and stroke” (NIH ODS).

In October 2026, FDA issued a final rule letting makers of standardized foods use safe and suitable salt substitutes in place of some or all added salt, effective December 14, 2026 (91 FR 65040). The rule does not name specific ingredients or limit them to potassium, and FDA says it cannot predict how much potassium in the food supply will change. Commenters raised concern about “hidden” potassium for people with kidney disease. FDA responded that potassium must appear on the Nutrition Facts label at 2% or more of the daily value per serving, and that potassium chloride must be named in the ingredient list, as “potassium chloride” or “potassium salt.”

Potassium is not named on the WADA 2026 Prohibited List. Diuretics, including furosemide, thiazides, spironolactone and triamterene, are prohibited under S5. Rules on IV infusions are covered on Electrolytes.

Key takeaways

  • The kidneys set the risk. Food potassium is not known to harm people with normal kidneys, and no upper limit exists, but the National Academies warns this does not mean high intake is free of risk.
  • Pills and salts differ widely. Most US supplements stop at 99 mg, largely because of FDA drug rules on bowel injury. Prescription tablets reach about 782 mg, and a teaspoon of salt substitute can hold up to about 2,800 mg.
  • Blood pressure effect is modest. Pooled trials show roughly 3–7 mm Hg lower systolic pressure, mostly with hypertension, with little effect without it and a possible reversal at very high supplement doses.
  • Salt substitutes have the strongest outcome data. SSaSS found 14% less stroke and 12% fewer deaths, but that one Chinese trial drives most of the evidence, and its safety data excluded people at known risk and did not capture lab-defined hyperkalemia.
  • Interactions cause the real harm. Spironolactone, ACE inhibitors, ARBs, trimethoprim and NSAIDs can all raise potassium, especially together or with kidney disease, and hyperkalemia can be silent until it stops the heart.
  • Cramps are a poor reason to supplement. No good evidence shows potassium prevents ordinary cramps, and cramps can occur with potassium that is too low or too high.

Sources

  1. National Academies of Sciences, Engineering, and Medicine. Dietary Reference Intakes for Sodium and Potassium. Washington, DC: National Academies Press; 2019. National Academies Press.
  2. National Institutes of Health Office of Dietary Supplements. Potassium: fact sheet for health professionals. Updated June 2, 2022. NIH ODS.
  3. Upsher-Smith Laboratories. Klor-Con M (potassium chloride extended-release tablets, USP), prescribing information. DailyMed.
  4. Mission Pharmacal. Urocit-K (potassium citrate) extended-release tablets, prescribing information. DailyMed.
  5. Pfizer. Aldactone (spironolactone) tablets, prescribing information. DailyMed.
  6. Upsher-Smith Laboratories. Zestril (lisinopril) tablets, prescribing information. DailyMed.
  7. Organon. Cozaar (losartan potassium) tablets, prescribing information. DailyMed.
  8. Validus Pharmaceuticals. Lasix (furosemide) tablets, prescribing information. DailyMed.
  9. PD-Rx Pharmaceuticals. Hydrochlorothiazide tablets, USP, prescribing information. DailyMed.
  10. Sun Pharmaceutical Industries. Bactrim and Bactrim DS (sulfamethoxazole and trimethoprim) tablets, prescribing information. DailyMed.
  11. GlaxoSmithKline. Ventolin HFA (albuterol sulfate) inhalation aerosol, prescribing information. DailyMed.
  12. Eli Lilly. Humulin R (insulin human) injection, prescribing information. DailyMed.
  13. Food and Drug Administration. 21 CFR 201.306: Potassium salt preparations intended for oral ingestion by man. Legal Information Institute.
  14. Food and Drug Administration. 21 CFR 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness. Legal Information Institute.
  15. Food and Drug Administration. Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods. Final rule. Federal Register. October 13, 2026;91:65040 (FR Doc 2026-20848). Federal Register.
  16. World Health Organization. Use of lower-sodium salt substitutes: WHO guideline. Geneva: World Health Organization; 2025. WHO.
  17. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114–e218. PubMed.
  18. Macdonald-Clarke CJ, Martin BR, McCabe LD, et al. Bioavailability of potassium from potatoes and potassium gluconate: a randomized dose response trial. Am J Clin Nutr. 2016;104(2):346–353. PubMed.
  19. Medbø JI, Sejersted OM. Plasma K+ changes during intense exercise in endurance-trained and sprint-trained subjects. Acta Physiol Scand. 1994;151(3):363–371. PubMed.
  20. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA. 1997;277(20):1624–1632. PubMed.
  21. Dickinson HO, Nicolson DJ, Campbell F, et al. Potassium supplementation for the management of primary hypertension in adults. Cochrane Database Syst Rev. 2006;(3):CD004641. PubMed.
  22. Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f1378. PubMed.
  23. Binia A, Jaeger J, Hu Y, et al. Daily potassium intake and sodium-to-potassium ratio in the reduction of blood pressure: a meta-analysis of randomized controlled trials. J Hypertens. 2015;33(8):1509–1520. PubMed.
  24. Filippini T, Violi F, D’Amico R, et al. The effect of potassium supplementation on blood pressure in hypertensive subjects: a systematic review and meta-analysis. Int J Cardiol. 2017;230:127–135. PubMed.
  25. Filippini T, Naska A, Kasdagli MI, et al. Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9(12):e015719. PubMed.
  26. Granal M, Sourd V, Burnier M, et al. Effect of changes in potassium intake on blood pressure: a dose-response meta-analysis of randomized clinical trials (2000-2024). Clin Kidney J. 2025;18(7):sfaf173. PubMed.
  27. Ravichagua Ashiyama J, Medina FA, Loza C, et al. Oral potassium supplementation lowers clinic blood pressure in untreated primary hypertension-systematic review and meta-analysis of randomized trials. J Am Heart Assoc. 2026;15(21):e048590. PubMed.
  28. Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021;385(12):1067–1077. PubMed.
  29. Ding X, Zhang X, Huang L, et al. Salt substitution and recurrent stroke and death: a randomized clinical trial. JAMA Cardiol. 2025;10(4):343–350. PubMed.
  30. Yuan Y, Jin A, Neal B, et al. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial. Nat Med. 2023;29(4):973–981. PubMed.
  31. Zhang X, Yuan Y, Li C, et al. Effect of a salt substitute on incidence of hypertension and hypotension among normotensive adults. J Am Coll Cardiol. 2024;83(7):711–722. PubMed.
  32. Brand A, Visser ME, Schoonees A, et al. Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women. Cochrane Database Syst Rev. 2022;8(8):CD015207. PubMed.
  33. Yin X, Rodgers A, Perkovic A, et al. Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis. Heart. 2022;108(20):1608–1615. PubMed.
  34. Lai H, Nesrallah G, Guyatt GH, et al. Comparative effects of salt substitutes on blood pressure, cardiovascular events and mortality: a systematic review and network meta-analysis. BMC Med. 2026;24(1):106. PubMed.
  35. Xu X, Zeng L, Jha V, et al. Potassium-enriched salt substitutes: a review of recommendations in clinical management guidelines. Hypertension. 2024;81(3):400–414. PubMed.
  36. Marklund M, Singh G, Greer R, et al. Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: modelling study. BMJ. 2020;369:m824. PubMed.
  37. Patil S, Falkowski A, Venkataiah VS, et al. The role of electrolytes in muscle pain syndromes: a systematic review and meta-analysis with implications for temporomandibular disorder. Int Dent J. 2026;76(3):109488. PubMed.
  38. Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2010;74(8):691–696. PubMed.
  39. Costa LDS, Correa VAF, de Oliveira VF, et al. Risk factors for exercise-associated muscle cramps: a systematic review with meta-analysis. Muscle Nerve. 2026;74(5):1375–1386. PubMed.
  40. Miller KC. Plasma potassium concentration and content changes after banana ingestion in exercised men. J Athl Train. 2012;47(6):648–654. PubMed.
  41. Garrison SR, Dormuth CR, Morrow RL, et al. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med. 2012;172(2):120–126. PubMed.
  42. Hoffman RJ, Hoffman RS, Freyberg CL, et al. Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels. J Toxicol Clin Toxicol. 2001;39(4):339–344. PubMed.
  43. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543–551. PubMed.
  44. Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2010;170(12):1045–1049. PubMed.
  45. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ. 2014;349:g6196. PubMed.
  46. Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ. 2015;187(4):E138–E143. PubMed.
  47. Crellin E, Mansfield KE, Leyrat C, et al. Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study. BMJ. 2018;360:k341. PubMed.
  48. Lim CC, Ang ATW, Kadir HBA, et al. Short-course systemic and topical non-steroidal anti-inflammatory drugs: impact on adverse renal events in older adults with co-morbid disease. Drugs Aging. 2021;38(2):147–156. PubMed.
  49. Gritter M, Wouda RD, Yeung SMH, et al. Effects of short-term potassium chloride supplementation in patients with CKD. J Am Soc Nephrol. 2022;33(9):1779–1789. PubMed.
  50. Morris A, Krishnan N, Kimani PK, et al. Corrected article: effect of dietary potassium restriction on serum potassium, disease progression, and mortality in chronic kidney disease: a systematic review and meta-analysis. J Ren Nutr. 2022;32(1):e1–e10. PubMed.
  51. Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42–61. PubMed.
  52. Bernier-Jean A, Salem SM, Clase C. Potassium intake and outcomes in people with chronic kidney disease: from diet to additives. Semin Nephrol. Published online September 29, 2026:151727. PubMed.
  53. Pfisterer N, Stöllberger C, Finsterer J. Severe acquired hypokalemic paralysis in a bodybuilder after self-medication with triamterene/hydrochlorothiazide. Clin J Sport Med. 2020;30(5):e172–e174. PubMed.
  54. Sturmi JE, Rutecki GW. When competitive bodybuilders collapse. Phys Sportsmed. 1995;23(11):49–53. PubMed.
  55. Appleby M, Fisher M, Martin M. Myocardial infarction, hyperkalaemia and ventricular tachycardia in a young male body-builder. Int J Cardiol. 1994;44(2):171–174. PubMed.
  56. World Anti-Doping Agency. The 2026 Prohibited List. WADA 2026 Prohibited List.